CHIC 2025 in Shanghai to focus on fashion innovations
Under the theme 'Fashion Picnic in Autumn,' CHIC 2025 (September) aims to focus on tapping into burgeoning markets, showcasing brands, leveraging digital tools, and fostering creative interactions.
Scheduled to take place from 2-4 September 2025, the event will feature more than 800 exhibitors across nine designed thematic zones spanning an area of more than 50,000m2.
The space hall will display Spring/Summer 2026 collections in various categories including women's, men's, and children's apparel, as well as accessories, shoes, and bags.
Some highlights include CHIC Talk, CHIC Shows, and an integrated digital WeChat Mini Program. The aim is to foster dialogue, spur innovation, and streamline networking within the industry.
CHIC Talk will feature a series of expert-led seminars and workshops offering a knowledge exchange platform. These sessions will bring together industry specialists and leading brands to discuss current trends in fashion.
Runway shows at the event will highlight creative designs for the upcoming season from premium brands and collective presentations by prominent national fashion organisations. These runway events aim to showcase the style acumen and capabilities of the participating labels.
The CHIC WeChat Mini programme will serve as a central digital tool for the fair, consolidating essential services such as visitor registration, business matching, and live stream broadcasting. This programme is extensively used by exhibitors, visitors, and partners as a crucial component of CHIC's digital infrastructure.
To date, CHIC has facilitated more than 1,000 matchmaking sessions and connected more than 600,000 trade visitors.
The spring edition of the fair in 2025, held from 11 to 13 March drew more than 1,175 exhibitors and a new high of over 165,000 visitors, with 55% attending CHIC for the first time.
The upcoming autumn edition aims to continue this momentum by organising targeted matchmaking meetings to explore new buyer potential and is anticipated to attract over 60,000 visitors.
"CHIC 2025 in Shanghai to focus on fashion innovations" was originally created and published by Just Style, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Soraban concludes Series A funding round
Soraban, an intelligent admin copilot designed for accounting firms, has closed its Series A funding round, with Altos Ventures leading the investment. The company said that the accounting sector is currently facing significant challenges, particularly in managing unbillable tasks that consume a substantial portion of the work week. Soraban aims to address this issue by automating the administrative processes that typically fall outside of billable hours. Unlike many automation tools that focus solely on tax-related tasks, Soraban is specifically engineered to streamline the administrative execution layer between tax software and clients. The platform facilitates various processes, including client intake, document collection, workflow coordination, and final delivery, thereby enabling firms to scale their operations more efficiently. Cathy Anderson, investor at Altos Ventures, said: 'Accounting firms aren't drowning in work, they're drowning in admin. 'Soraban doesn't just automate tasks; it rebuilds the back office from the client's point of view. Because when the client experience works, everything else does too—less chasing, more billing, and happier teams. 'That clarity comes from Enoch, an engineer and former accounting firm owner who's felt the pain firsthand. If you want to scale without the chaos, Soraban is the only tool you need.' By automating manual tasks that are often delegated to administrative staff or outsourced, Soraban not only reduces the burden on accounting firms but also simplifies work that previously required skilled accounting personnel. This innovation allows administrative staff to concentrate on enhancing client experiences, ultimately increasing capacity without the need for additional headcount and allowing teams to focus on revenue-generating activities. Soraban founder and CEO Enoch Ko said: 'At Soraban, our mission is to eliminate the manual busywork that's draining accountants and admins — and costing firms real money. 'The industry is hitting a wall. There simply aren't enough great professionals to keep up with demand. While others are still testing, Soraban has already gone through five tax seasons and is powering over 300 firms. 'This investment gives us the firepower to scale across more workflows and deliver a smarter, faster future for the profession.' "Soraban concludes Series A funding round" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Eli Lilly and GSK drive South Korea's drug licensing activity
China's growth as a drug licensing hub is well-treaded, but a surge in deals in South Korea means it is also becoming a go-to destination for big pharma companies, according to market analysis. According to the GlobalData deal database, the deal value for South Korean drug licensing agreements has so far reached $7.68bn this year, marking a 113% increase from 2024. The out-licensing of South Korean drugs to international firms surged by 180%, around a $5.1bn increase, from 2024 to so far in 2025. The momentum in out-licensing was largely fuelled by billion-dollar agreements among large pharma companies such as Eli Lilly and GSK. Eli Lilly outlaid $630m for OliX Pharmaceuticals' metabolic-associated steatohepatitis (MASH) candidate in February and agreed a separate $1.3bn deal for biotech Rznomics' RNA-based gene therapies in May. GSK meanwhile licensed ABL Bios' blood-brain barrier shuttle platform for $2.8bn in April. GlobalData senior business fundamentals analyst Ophelia Chan says: 'Once primarily recognised for generic drug production, South Korea is now transitioning into a global hub for novel innovative drug discovery and advanced drug technologies, bolstered by government support and increasing international investment. This transition positions the country as a strategic bridge between Western and Asian markets.' In January 2025, South Korea established the National Bio Committee to make the country one of five global leaders in the bio industry by 2035. Part of this mandate is to enhance the country's competitiveness in novel drug and advanced biopharmaceutical technology development. According to South Korea's Ministry of Science and IT, the committee plans to create a Won1tn ($695.7m) fund to promote private investment in the biopharmaceutical and vaccine industry. The initiative builds on ongoing reforms as the government aims to reduce drug development timelines and costs, GlobalData said. South Korea joins China as a fast-growing destination for promising pipeline drug candidates. The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020. A bipartisan report in the US has called for at least $15bn of funding over the next five years to avoid being eclipsed by China in biotech advancement. The future of the US and European pharma industries' relationship with Chinese and South Korean companies will require sturdy trade relationships between the regions. This has been stretched this year with tariffs imposed by President Donald Trump as his administration looks to bolster domestic manufacturing in the US. While licensing deals do not equate to imported products, Trump has maintained that transferring technology to China poses a threat to national security. The controversial BIOSECURE Act, which would have blacklisted Chinese biotechs and manufacturers from accessing US funding and collaborating with US pharma companies, is still in regulatory limbo. Another announcement made by the US Food and Drug Administration (FDA) was for an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into US patients. This move may potentially impact deals that pharma and biotech's have in place with Chinese contract development and manufacturing organisations (CDMOs). "Eli Lilly and GSK drive South Korea's drug licensing activity" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
4 days ago
- Yahoo
BEV sales in South Korea rebounding strongly in 2025
Sales of battery electric vehicles (BEVs) in South Korea surged by 67% year-on-year to 25,148 units in July, according to local reports citing data compiled by Carisyou Data Research. The company said the local BEV market is rebounding from a prolonged downturn, driven by new models. BEV sales in South Korea amounted to 118,717 units in the first seven months of the year, compared with 146,883 units in the whole of 2024. Average monthly sales surged to 16,960 units – up from 12,240 units in 2024, and surpassing the previous peak of 13,707 in 2022. The recovery in the BEV market has been attributed to a wave of new model launches this year, including the Hyundai Ioniq 9 which was in February, and the Kia EV4 sedan launched in March. Slightly older models such as the Kia EV3, launched in July 2024, and the Kia Ray, have also performed strongly this year. Foreign brands have also performed well, including the updated Tesla Model Y – which is currently the best-selling BEV model in the country. "BEV sales in South Korea rebounding strongly in 2025" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
